Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
The price of Arbutus Biopharma Corp (NASDAQ: ABUS) closed at $2.64 in the last session, down -2.94% from day before closing price of $2.72. In other words, the price has decreased by $-2.94 from its previous closing price. On the day, 0.74 million shares were traded. ABUS stock price reached its highest trading level at $2.74 during the session, while it also had its lowest trading level at $2.635.
Ratios:
We take a closer look at ABUS’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 5.87 and its Current Ratio is at 5.87. In the meantime, Its Debt-to-Equity ratio is 0.08 whereas as Long-Term Debt/Eq ratio is at 0.08.
On February 25, 2021, Jefferies started tracking the stock assigning a Hold rating and target price of $5.
On December 17, 2020, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $10.H.C. Wainwright initiated its Buy rating on December 17, 2020, with a $10 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Feb 02 ’24 when McElhaugh Michael J. sold 10,164 shares for $2.31 per share. The transaction valued at 23,504 led to the insider holds 1,504,793 shares of the business.
Sofia Michael J. sold 9,982 shares of ABUS for $23,083 on Feb 02 ’24. The Chief Scientific Officer now owns 1,485,121 shares after completing the transaction at $2.31 per share. On Feb 02 ’24, another insider, HASTINGS DAVID C, who serves as the Chief Financial Officer of the company, sold 9,593 shares for $2.31 each. As a result, the insider received 22,184 and left with 181,907 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ABUS now has a Market Capitalization of 475662048 and an Enterprise Value of 370936768. For the stock, the TTM Price-to-Sale (P/S) ratio is 26.22 while its Price-to-Book (P/B) ratio in mrq is 4.23. Its current Enterprise Value per Revenue stands at 20.447 whereas that against EBITDA is -4.841.
Stock Price History:
The Beta on a monthly basis for ABUS is 2.03, which has changed by -0.058823526 over the last 52 weeks, in comparison to a change of 0.2006725 over the same period for the S&P500. Over the past 52 weeks, ABUS has reached a high of $3.29, while it has fallen to a 52-week low of $1.69. The 50-Day Moving Average of the stock is -4.78%, while the 200-Day Moving Average is calculated to be 16.77%.
Shares Statistics:
According to the various share statistics, ABUS traded on average about 1.41M shares per day over the past 3-months and 1159200 shares per day over the past 10 days. A total of 169.87M shares are outstanding, with a floating share count of 137.52M. Insiders hold about 23.67% of the company’s shares, while institutions hold 43.67% stake in the company. Shares short for ABUS as of 1711584000 were 4546180 with a Short Ratio of 3.22, compared to 1709164800 on 4065797. Therefore, it implies a Short% of Shares Outstanding of 4546180 and a Short% of Float of 3.3000000000000003.
Earnings Estimates
The market rating for Arbutus Biopharma Corp (ABUS) is a result of the insights provided by Alpha Blue Capital US Small-Mid analysts actively involved in the assessment.The consensus estimate for the next quarter is $2.64, with high estimates of $93.49 and low estimates of $1.92.
